Health and Fitness Health and Fitness
Thu, January 5, 2012
[ Thu, Jan 05th 2012 ] - Market Wire
3DGO!
Wed, January 4, 2012

NuPathe to Present at Biotech Showcase 2012


Published on 2012-01-04 13:27:05 - Market Wire
  Print publication without navigation


January 04, 2012 16:20 ET

NuPathe to Present at Biotech Showcase 2012

CONSHOHOCKEN, PA--(Marketwire - Jan 4, 2012) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present a company overview at Biotech Showcase 2012 on Wednesday, January 11, 2012, at 2:00 p.m. EST. The conference is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.

About NuPathe
[ NuPathe ] Inc. ([ www.nupathe.com ]) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.